B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses
Identifieur interne : 002322 ( Istex/Corpus ); précédent : 002321; suivant : 002323B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses
Auteurs : Kathleen P. Pratt ; Arthur R. ThompsonSource :
- Clinical Reviews in Allergy & Immunology [ 1080-0549 ] ; 2009-10-01.
English descriptors
Abstract
Abstract: Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred to clinically as “inhibitors,” interfere with its procoagulant activity. Inhibitors are the subset of anti-FVIII antibodies that bind to surfaces on FVIII (B-cell epitopes) that are important for its proper functioning in coagulation. Less antigenic FVIII molecules may be designed by identifying and then modifying the amino acid sequences of inhibitor B-cell epitopes. Conversely, characterization of these epitopes can yield important information regarding functionally important surfaces on FVIII. The production of inhibitor antibodies is driven by T cells. T cells recognize FVIII as foreign when FVIII-derived peptides bind to major histocompatibility complex (MHC) class II molecules on the surface of antigen-presenting cells. The class II–peptide complexes must then be recognized by T-cell receptors (TCRs). T-cell stimulation requires sustained association of antigen-presenting cells and T cells through formation of a class II–peptide–TCR complex, and peptide sequences that mediate this association are termed “T-cell epitopes.” MHC class II tetramers that bind FVIII-derived peptides and recognize antigen-specific TCRs are proving useful in the characterization of human leukocyte antigen-restricted T-cell responses to FVIII.
Url:
DOI: 10.1007/s12016-009-8120-7
Links to Exploration step
ISTEX:B7EC6E591B22233D0A7F133465CA9E6E14908A0DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</title><author><name sortKey="Pratt, Kathleen P" sort="Pratt, Kathleen P" uniqKey="Pratt K" first="Kathleen P." last="Pratt">Kathleen P. Pratt</name><affiliation><mods:affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: kathleenp@psbcresearch.org</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Arthur R" sort="Thompson, Arthur R" uniqKey="Thompson A" first="Arthur R." last="Thompson">Arthur R. Thompson</name><affiliation><mods:affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B7EC6E591B22233D0A7F133465CA9E6E14908A0D</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1007/s12016-009-8120-7</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-H00V6SSC-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002322</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002322</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</title><author><name sortKey="Pratt, Kathleen P" sort="Pratt, Kathleen P" uniqKey="Pratt K" first="Kathleen P." last="Pratt">Kathleen P. Pratt</name><affiliation><mods:affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: kathleenp@psbcresearch.org</mods:affiliation></affiliation></author><author><name sortKey="Thompson, Arthur R" sort="Thompson, Arthur R" uniqKey="Thompson A" first="Arthur R." last="Thompson">Arthur R. Thompson</name><affiliation><mods:affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Reviews in Allergy & Immunology</title><title level="j" type="abbrev">Clinic Rev Allerg Immunol</title><idno type="ISSN">1080-0549</idno><idno type="eISSN">1559-0267</idno><imprint><publisher>Humana Press Inc</publisher><pubPlace>New York</pubPlace><date type="published" when="2009-10-01">2009-10-01</date><biblScope unit="volume">37</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="80">80</biblScope><biblScope unit="page" to="95">95</biblScope></imprint><idno type="ISSN">1080-0549</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1080-0549</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>B-cell epitopes</term><term>Hemophilia A</term><term>Inhibitory antibody</term><term>T-cell immune responses</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred to clinically as “inhibitors,” interfere with its procoagulant activity. Inhibitors are the subset of anti-FVIII antibodies that bind to surfaces on FVIII (B-cell epitopes) that are important for its proper functioning in coagulation. Less antigenic FVIII molecules may be designed by identifying and then modifying the amino acid sequences of inhibitor B-cell epitopes. Conversely, characterization of these epitopes can yield important information regarding functionally important surfaces on FVIII. The production of inhibitor antibodies is driven by T cells. T cells recognize FVIII as foreign when FVIII-derived peptides bind to major histocompatibility complex (MHC) class II molecules on the surface of antigen-presenting cells. The class II–peptide complexes must then be recognized by T-cell receptors (TCRs). T-cell stimulation requires sustained association of antigen-presenting cells and T cells through formation of a class II–peptide–TCR complex, and peptide sequences that mediate this association are termed “T-cell epitopes.” MHC class II tetramers that bind FVIII-derived peptides and recognize antigen-specific TCRs are proving useful in the characterization of human leukocyte antigen-restricted T-cell responses to FVIII.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Kathleen P. Pratt</name><affiliations><json:string>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</json:string><json:string>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</json:string><json:string>E-mail: kathleenp@psbcresearch.org</json:string></affiliations></json:item><json:item><name>Arthur R. Thompson</name><affiliations><json:string>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</json:string><json:string>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Hemophilia A</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Inhibitory antibody</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>B-cell epitopes</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>T-cell immune responses</value></json:item></subject><articleId><json:string>8120</json:string><json:string>s12016-009-8120-7</json:string></articleId><arkIstex>ark:/67375/VQC-H00V6SSC-K</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred to clinically as “inhibitors,” interfere with its procoagulant activity. Inhibitors are the subset of anti-FVIII antibodies that bind to surfaces on FVIII (B-cell epitopes) that are important for its proper functioning in coagulation. Less antigenic FVIII molecules may be designed by identifying and then modifying the amino acid sequences of inhibitor B-cell epitopes. Conversely, characterization of these epitopes can yield important information regarding functionally important surfaces on FVIII. The production of inhibitor antibodies is driven by T cells. T cells recognize FVIII as foreign when FVIII-derived peptides bind to major histocompatibility complex (MHC) class II molecules on the surface of antigen-presenting cells. The class II–peptide complexes must then be recognized by T-cell receptors (TCRs). T-cell stimulation requires sustained association of antigen-presenting cells and T cells through formation of a class II–peptide–TCR complex, and peptide sequences that mediate this association are termed “T-cell epitopes.” MHC class II tetramers that bind FVIII-derived peptides and recognize antigen-specific TCRs are proving useful in the characterization of human leukocyte antigen-restricted T-cell responses to FVIII.</abstract><qualityIndicators><score>9.448</score><pdfWordCount>11929</pdfWordCount><pdfCharCount>76693</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>16</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>204</abstractWordCount><abstractCharCount>1502</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</title><genre><json:string>research-article</json:string></genre><host><title>Clinical Reviews in Allergy & Immunology</title><language><json:string>unknown</json:string></language><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><issn><json:string>1080-0549</json:string></issn><eissn><json:string>1559-0267</json:string></eissn><journalId><json:string>12016</json:string></journalId><volume>37</volume><issue>2</issue><pages><first>80</first><last>95</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Internal Medicine</value></json:item><json:item><value>Immunology</value></json:item><json:item><value>Allergology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-H00V6SSC-K</json:string></ark><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1007/s12016-009-8120-7</json:string></doi><id>B7EC6E591B22233D0A7F133465CA9E6E14908A0D</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-H00V6SSC-K/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-H00V6SSC-K/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-H00V6SSC-K/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Humana Press Inc</publisher><pubPlace>New York</pubPlace><availability><licence><p>Humana Press Inc., 2009</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2009</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Kathleen</forename><surname>Pratt</surname></persName><email>kathleenp@psbcresearch.org</email><affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</affiliation><affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Arthur</forename><surname>Thompson</surname></persName><affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</affiliation><affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</affiliation></author><idno type="istex">B7EC6E591B22233D0A7F133465CA9E6E14908A0D</idno><idno type="ark">ark:/67375/VQC-H00V6SSC-K</idno><idno type="DOI">10.1007/s12016-009-8120-7</idno><idno type="article-id">8120</idno><idno type="article-id">s12016-009-8120-7</idno></analytic><monogr><title level="j">Clinical Reviews in Allergy & Immunology</title><title level="j" type="abbrev">Clinic Rev Allerg Immunol</title><idno type="pISSN">1080-0549</idno><idno type="eISSN">1559-0267</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">9</idno><idno type="volume-issue-count">3</idno><imprint><publisher>Humana Press Inc</publisher><pubPlace>New York</pubPlace><date type="published" when="2009-10-01"></date><biblScope unit="volume">37</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="80">80</biblScope><biblScope unit="page" to="95">95</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred to clinically as “inhibitors,” interfere with its procoagulant activity. Inhibitors are the subset of anti-FVIII antibodies that bind to surfaces on FVIII (B-cell epitopes) that are important for its proper functioning in coagulation. Less antigenic FVIII molecules may be designed by identifying and then modifying the amino acid sequences of inhibitor B-cell epitopes. Conversely, characterization of these epitopes can yield important information regarding functionally important surfaces on FVIII. The production of inhibitor antibodies is driven by T cells. T cells recognize FVIII as foreign when FVIII-derived peptides bind to major histocompatibility complex (MHC) class II molecules on the surface of antigen-presenting cells. The class II–peptide complexes must then be recognized by T-cell receptors (TCRs). T-cell stimulation requires sustained association of antigen-presenting cells and T cells through formation of a class II–peptide–TCR complex, and peptide sequences that mediate this association are termed “T-cell epitopes.” MHC class II tetramers that bind FVIII-derived peptides and recognize antigen-specific TCRs are proving useful in the characterization of human leukocyte antigen-restricted T-cell responses to FVIII.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Hemophilia A</term></item><item><term>Inhibitory antibody</term></item><item><term>B-cell epitopes</term></item><item><term>T-cell immune responses</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Internal Medicine</term></item><item><term>Immunology</term></item><item><term>Allergology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-10-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-H00V6SSC-K/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Humana Press Inc</PublisherName><PublisherLocation>New York</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>12016</JournalID><JournalPrintISSN>1080-0549</JournalPrintISSN><JournalElectronicISSN>1559-0267</JournalElectronicISSN><JournalTitle>Clinical Reviews in Allergy & Immunology</JournalTitle><JournalAbbreviatedTitle>Clinic Rev Allerg Immunol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Internal Medicine </JournalSubject><JournalSubject Type="Secondary">Immunology</JournalSubject><JournalSubject Type="Secondary">Allergology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>37</VolumeIDStart><VolumeIDEnd>37</VolumeIDEnd><VolumeIssueCount>3</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>2</IssueIDStart><IssueIDEnd>2</IssueIDEnd><IssueTitle Language="En">Anti-Factor VIII Antibodies (Inhibitors) in Hemophilia; Guest Editor: Svini V. Kaveri</IssueTitle><IssueArticleCount>9</IssueArticleCount><IssueHistory><OnlineDate><Year>2009</Year><Month>9</Month><Day>11</Day></OnlineDate><PrintDate><Year>2009</Year><Month>9</Month><Day>10</Day></PrintDate><CoverDate><Year>2009</Year><Month>10</Month></CoverDate><PricelistYear>2009</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Humana Press Inc.</CopyrightHolderName><CopyrightYear>2009</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s12016-009-8120-7" OutputMedium="All"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>8120</ArticleID><ArticleDOI>10.1007/s12016-009-8120-7</ArticleDOI><ArticleSequenceNumber>4</ArticleSequenceNumber><ArticleTitle Language="En">B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</ArticleTitle><ArticleFirstPage>80</ArticleFirstPage><ArticleLastPage>95</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2009</Year><Month>1</Month><Day>5</Day></RegistrationDate><OnlineDate><Year>2009</Year><Month>1</Month><Day>30</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Humana Press Inc.</CopyrightHolderName><CopyrightYear>2009</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1 Aff2" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Kathleen</GivenName><GivenName>P.</GivenName><FamilyName>Pratt</FamilyName></AuthorName><Contact><Email>kathleenp@psbcresearch.org</Email></Contact></Author><Author AffiliationIDS="Aff1 Aff2"><AuthorName DisplayOrder="Western"><GivenName>Arthur</GivenName><GivenName>R.</GivenName><FamilyName>Thompson</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgName>Puget Sound Blood Center</OrgName><OrgAddress><Street>921 Terry Ave</Street><City>Seattle</City><State>WA</State><Postcode>98104-1256</Postcode><Country Code="US">USA</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Division of Hematology, Dept. Medicine</OrgDivision><OrgName>University of Washington</OrgName><OrgAddress><City>Seattle</City><State>WA</State><Country Code="US">USA</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Abstract</Heading><Para>Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred to clinically as “inhibitors,” interfere with its procoagulant activity. Inhibitors are the subset of anti-FVIII antibodies that bind to surfaces on FVIII (B-cell epitopes) that are important for its proper functioning in coagulation. Less antigenic FVIII molecules may be designed by identifying and then modifying the amino acid sequences of inhibitor B-cell epitopes. Conversely, characterization of these epitopes can yield important information regarding functionally important surfaces on FVIII. The production of inhibitor antibodies is driven by T cells. T cells recognize FVIII as foreign when FVIII-derived peptides bind to major histocompatibility complex (MHC) class II molecules on the surface of antigen-presenting cells. The class II–peptide complexes must then be recognized by T-cell receptors (TCRs). T-cell stimulation requires sustained association of antigen-presenting cells and T cells through formation of a class II–peptide–TCR complex, and peptide sequences that mediate this association are termed “T-cell epitopes.” MHC class II tetramers that bind FVIII-derived peptides and recognize antigen-specific TCRs are proving useful in the characterization of human leukocyte antigen-restricted T-cell responses to FVIII.</Para></Abstract><KeywordGroup Language="En"><Heading>Keywords</Heading><Keyword>Hemophilia A</Keyword><Keyword>Inhibitory antibody</Keyword><Keyword>B-cell epitopes</Keyword><Keyword>T-cell immune responses</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Kathleen</namePart><namePart type="given">P.</namePart><namePart type="family">Pratt</namePart><affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</affiliation><affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</affiliation><affiliation>E-mail: kathleenp@psbcresearch.org</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Arthur</namePart><namePart type="given">R.</namePart><namePart type="family">Thompson</namePart><affiliation>Puget Sound Blood Center, 921 Terry Ave, 98104-1256, Seattle, WA, USA</affiliation><affiliation>Division of Hematology, Dept. Medicine, University of Washington, Seattle, WA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Humana Press Inc</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2009-10-01</dateIssued><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients develop an immune response in which anti-FVIII antibodies, referred to clinically as “inhibitors,” interfere with its procoagulant activity. Inhibitors are the subset of anti-FVIII antibodies that bind to surfaces on FVIII (B-cell epitopes) that are important for its proper functioning in coagulation. Less antigenic FVIII molecules may be designed by identifying and then modifying the amino acid sequences of inhibitor B-cell epitopes. Conversely, characterization of these epitopes can yield important information regarding functionally important surfaces on FVIII. The production of inhibitor antibodies is driven by T cells. T cells recognize FVIII as foreign when FVIII-derived peptides bind to major histocompatibility complex (MHC) class II molecules on the surface of antigen-presenting cells. The class II–peptide complexes must then be recognized by T-cell receptors (TCRs). T-cell stimulation requires sustained association of antigen-presenting cells and T cells through formation of a class II–peptide–TCR complex, and peptide sequences that mediate this association are termed “T-cell epitopes.” MHC class II tetramers that bind FVIII-derived peptides and recognize antigen-specific TCRs are proving useful in the characterization of human leukocyte antigen-restricted T-cell responses to FVIII.</abstract><subject lang="en"><genre>Keywords</genre><topic>Hemophilia A</topic><topic>Inhibitory antibody</topic><topic>B-cell epitopes</topic><topic>T-cell immune responses</topic></subject><relatedItem type="host"><titleInfo><title>Clinical Reviews in Allergy & Immunology</title></titleInfo><titleInfo type="abbreviated"><title>Clinic Rev Allerg Immunol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2009-09-11</dateIssued><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><subject><genre>Medicine & Public Health</genre><topic>Internal Medicine</topic><topic>Immunology</topic><topic>Allergology</topic></subject><identifier type="ISSN">1080-0549</identifier><identifier type="eISSN">1559-0267</identifier><identifier type="JournalID">12016</identifier><identifier type="IssueArticleCount">9</identifier><identifier type="VolumeIssueCount">3</identifier><part><date>2009</date><detail type="issue"><title>Anti-Factor VIII Antibodies (Inhibitors) in Hemophilia; Guest Editor: Svini V. Kaveri</title></detail><detail type="volume"><number>37</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="pages"><start>80</start><end>95</end></extent></part><recordInfo><recordOrigin>Humana Press Inc., 2009</recordOrigin></recordInfo></relatedItem><identifier type="istex">B7EC6E591B22233D0A7F133465CA9E6E14908A0D</identifier><identifier type="ark">ark:/67375/VQC-H00V6SSC-K</identifier><identifier type="DOI">10.1007/s12016-009-8120-7</identifier><identifier type="ArticleID">8120</identifier><identifier type="ArticleID">s12016-009-8120-7</identifier><accessCondition type="use and reproduction" contentType="copyright">Humana Press Inc., 2009</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Humana Press Inc., 2009</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-H00V6SSC-K/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002322 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002322 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B7EC6E591B22233D0A7F133465CA9E6E14908A0D
|texte= B-Cell and T-Cell Epitopes in Anti-factor VIII Immune Responses
}}
| This area was generated with Dilib version V0.6.33. |  |